Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma.

J Natl Cancer Inst 2007 Jun 12;99(12):936-48. Epub 2007 Jun 12.

Department of Chemistry, Open Laboratory of Chemical Biology, The University of Hong Kong, Pokfulam, Hong Kong, China.

Background: Median survival for patients with glioblastoma multiforme, the most aggressive glioma, is only 12-15 months, despite multimodal treatment that includes surgery, chemotherapy, and radiotherapy. Thus, identification of genes that control the progression of glioblastoma multiforme is crucial for devising new therapies. We investigated the involvement of cell cycle-related kinase (CCRK), a novel protein kinase that is homologous to cyclin-dependent kinase 7, in glioblastoma multiforme carcinogenesis.

Methods: We analyzed the expression levels of CCRK in 26 glioma patient samples (19 high-grade and seven low-grade) and normal brain by semiquantitative reverse transcription-polymerase chain reaction assays. CCRK expression was knocked down in human glioma U-373 MG and U-87 MG cells with small-interfering RNAs and short hairpin RNAs (siCCRK and shCCRK, respectively), and cell proliferation, cell cycle distribution, and cyclin-dependent kinase 2 (CDK2) phosphorylation were examined. A subcutaneous nude mouse xenograft model (n = 4 mice per group) was used to study the effect of CCRK knockdown and overexpression on tumorigenicity and growth of glioblastoma multiforme cells in vivo. All statistical tests were two-sided.

Results: CCRK mRNA was elevated at least 1.5-fold and as much as 3.7-fold in 14 (74%) of 19 high-grade glioblastoma multiforme patient samples and in four (80%) of five glioma cell lines examined compared with normal brain tissue. Suppression of CCRK by siCCRK inhibited the proliferation of U-373 MG and U-87 MG glioblastoma cells in a time- and dose-dependent manner. The growth-inhibiting effect of siCCRK was mediated via G1- to S-phase cell cycle arrest and reduced CDK2 phosphorylation. CCRK knockdown statistically significantly suppressed glioma cell growth in vivo as indicated by the mean tumor volumes at week 6 after tumor cell injection (U-373-control = 1352 mm3, U-373-shCCRK = 294 mm3, difference = 1058 mm3, 95% confidence interval [CI] = 677 to 1439 mm3, P<.001; U-87-control = 1910 mm3, U-87-shCCRK = 552 mm3, difference = 1358 mm3, 95% CI = 977 to 1739 mm3, P<.001).

Conclusions: CCRK is a candidate oncogene in glioblastoma multiforme tumorigenesis.

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djm011DOI Listing
June 2007
35 Reads

Publication Analysis

Top Keywords

glioblastoma multiforme
20
cdk2 phosphorylation
8
glioma cell
8
cell cycle
8
cyclin-dependent kinase
8
cell
8
normal brain
8
patient samples
8
cell cycle-related
8
cycle-related kinase
8
ccrk knockdown
8
u-373 u-87
8
glioblastoma
7
ccrk
7
glioma
5
multiforme
5
kinase
5
knockdown overexpression
4
cells vivo
4
growth glioblastoma
4

References

(Supplied by CrossRef)

Behin et al.
Lancet 2003

Maher et al.
Genes & Development 2001

Stupp et al.
New England Journal of Medicine 2005

Wong et al.
PNAS 1992

Fujisawa et al.
Laboratory investigation; a journal of technical methods and pathology 2000

Nakamura et al.
Journal of neuropathology and experimental neurology 2000

Reifenberger et al.
Cancer Research 1993

Jen et al.
Cancer Research 1994

Watanabe et al.
Clinical Cancer Research 1997

Hermanson et al.
Cancer Research 1996

Tohma et al.
Journal of neuropathology and experimental neurology 1998

Similar Publications